Bullish Case: ACLS at $113.15 sits ~33% below its 90-day level after a sharp de-rating, yet October call volume dominates (120C/130C, IV ~57-59%) and calls out-trade puts by 79%. The Helium density shows a fat right tail toward $130-145, and AI/DRAM-driven implant demand plus oversold mean reversion could drive a snap back toward $125-135 if the next earnings print stabilizes guidance.

Bearish Case: The Helium density peaks near $105 with mode below spot, the return surface carries heavy negative-return mass, and the term structure is in backwardation with elevated put IV (Nov 85P ~73%, Dec 55-65P >85%)—market pricing idiosyncratic downside. Muted semi-cap orders, China/regulatory overhang, and my historically overestimated upside calls argue the de-rating continues.

Potential Outcomes:

1. Chop $105-125 (40%): IV bleeds into Oct 16 expiry; falsify if spot holds >120 with rising ATM call IV.
2. Drift to $95-105 (25%): soft demand/margins deepen the downtrend; falsify if Oct 95P IV collapses.
3. Relief rally $125-140 (20%): guidance/catalyst, call-driven; falsify on failed break above $120.
4. Shock <$95 (15%): China/regulatory or macro risk-off; put skew steepens further.

September 22, 2026